GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

September 20, 2019 Articles 7:21 pm

Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises efficacy across a spectrum of mood disorders, particularly anxiety and depression.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit